`Home address:
`
`5411 North Capitol Avenue
`Indianapolis, Indiana 46208
`(317) 840‐2849
`
`
`CURRICULUM VITAE
`
`CHRISTOPHER A. FAUSEL, Pharm.D. MHA BCOP
`January 2016
`
`
`
`
`
`
`
`
`
`
`
` address:
` Office
`
` University Simon Cancer Center C2324
` Indiana
`West Michigan Street
` 1030
` Indianapolis,
` Indiana 46202‐5277
`Phone: (317) 948‐6866
`Fax: (317) 948‐4989
`Pager: (317) 312‐6356
`E‐mail: cfausel@iuhealth.org
`
`
`
`
`
`Education:
`
`Graduate:
`
`Masters of Health Administration, January 2011 – May 2013. Simmons College, Boston,
`Massachusetts (with honors).
`
`Pharmacy Leadership Academy, American Society of Health‐System Phamacists. January 2011 –
`April 2012.
`
`Doctor of Pharmacy. September 1994 ‐ June 1996. Albany College of Pharmacy, Albany, New York.
`
`Undergraduate:
`
`B.S. Pharmacy. September 1988 ‐ May 1993. Albany College of Pharmacy, Albany, New York.
`
`Work Experience:
`
`January 2011 – present.
`
`
`Clinical Manager, Oncology Pharmacy
`Indiana University Health
`Indianapolis, Indiana.
`
`Dr. Reddy’s Laboratories, Ltd., et al.
`v.
`Helsinn Healthcare S.A., et al.
`U.S. Patent No. 9,(cid:20)(cid:26)(cid:22),(cid:28)(cid:23)(cid:21)
`Reddy Exhibit 1039
`
`Exh. 1039, Page 1 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 2
`
`July 2008 – December 2010.
`
`
`Clinical Director, Oncology Pharmacy Services
`Indiana University Simon Cancer Center
`Division of Hematology/Oncology, Department of Medicine
`Indiana University School of Medicine
`Indianapolis, Indiana.
`
`October 1996 – July 2008.
`
`
`Clinical pharmacist, Adult Hematology/Oncology/Bone Marrow Transplant
`Indiana University Hospital
`Clarian Health Partners
`Indianapolis, Indiana.
`
`
`July 1994 ‐ September 1996.
`
`
`
`Staff pharmacist (part time)
`
`Samuel Stratton VA Medical Center
`
`Albany, New York.
`
`July 1993 ‐ July 1994.
`
`ASHP Pharmacy Practice Residency
`Samuel Stratton VA Medical Center
`Albany, New York
`Mary H. Andritz Pharm.D. FASHP, Residency Director.
`
`
`December 1989 ‐ June 1993.
`
`Pharmacy Intern
`Samuel S. Stratton VA Medical Center
`Albany, New York.
`
`
`Licensure:
`
`Indiana, September 1996 ‐ present.
`
`New York, September 1993 ‐ present.
`
`
`Exh. 1039, Page 2 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 3
`
`Certifications:
`
`Board Certified Oncology Pharmacist (BCOP), December, 1999. Recertification 2006, 2013.
`
`Board Certified Pharmacotherapy Specialist (BCPS), December 1998 – December 2012. (retired)
`
`Advanced Cardiac Life Support. American Red Cross. August 2013 – present.
`
`Basic Life Support. American Red Cross. December 2012 ‐ present.
`
`Appointments:
`
`Academic:
`
`
`Indiana University School of Medicine, Department of Medicine, Division of
`Hematology/Oncology: Adjunct Associate Professor of Medicine. November 2000 –
`present.
`
`
`
`
`
`
`
`Butler University ‐ College of Pharmacy and Health Sciences: Assistant Adjunct Professor of
`Pharmacy ‐ April 1997 – present.
`
`Purdue University ‐ School of Pharmacy and Pharmacal Sciences: Affiliate Assistant
`Professor of Clinical Pharmacy ‐ April 1997 – present.
`
`Professional Service:
`
`Chairman of the Board. Hoosier Oncology Group. July 2013 – present.
`
`National Marrow Donor Program – System Capacity Initiative – to increase pharmacist
`workforce in Stem Cell Transplantation September 2011 – present.
`
`Hematology Oncology Pharmacists Association‐ Nominations and Awards Committee.
`January 2011 – December 2012. January 2015‐ present.
`
`Editorial Board, Clinical Controversies. Journal of Hematology/Oncology Pharmacy. October
`2010 – present.
`
`Executive Committee, IUPUI IRB. July 2010 – present.
`
`Academic Health Complex Pharmacy and Therapeutics Committee, Indiana University
`Health. July 2010 – present.
`
`Exh. 1039, Page 3 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 4
`
`
`ASHP PGY2 Oncology Pharmacy Residency accreditation site reviewer. September 2008 –
`present.
`
`Reviewer. Bone Marrow Transplantation. Nature publications. January 2007 – present.
`
`Editorial Board. Guide to the management of selected adverse events associated with
`cancer chemotherapy, RJM Associates. June 2001 – June 2012.
`
`
`
`
`
`Central Institutional Review Board, National Cancer Institute, Bethesda, Maryland.
`Scientific member. July 2000 – October 2004.
`
`Hematology/Oncology Pharmacist Editor. Lippincott Williams and Wilkens ‐ Springhouse
`Medical Publications. May 2000 – 2008.
`
`Hoosier Oncology Group Supportive Care Committee. January 2000 – present.
`
`Eastern Cooperative Oncology Group (ECOG). Pharmacy committee. Voting member
`November 1998 – present. Co‐Chair, November 2001 – November 2003, Chair, November
`2003 – November 2005. Multiple Myeloma Core Committee, November 2002 – present.
`
`Scientific Review Committee, Indiana University Cancer Center, Indianapolis, Indiana.
`Voting member. July 1998 – present.
`
`Institutional Review Board, Indiana University Purdue University at Indianapolis,
`Indianapolis, Indiana. July 1997 – present. Chair – IRB 05 and IRB 07 Emergency
`Committee.
`
`
`Ongoing Research:
`
`Albany C, Hanna NH, Picus J, Hauke RJ, Fausel CA, Liu Z, Brames MJ, Einhorn LH. Phase II study
`of fosaprepitant + 5HT3 receptor antagonists + dexamethasone in patients with germ cell
`tumors undergoing 5‐day cisplatin‐based chemotherapy: Hoosier oncology group QL12‐153.
`
`Khawaja MR, Cripe LD, Schwartz JE, Kiel PJ, Fausel CA, Sayar H, Robertson MJ, Abonour R,
`Cornetta K, Farag S, Nelson RP Jr. Cyclophosphamide/fludarabine‐based nonmyeloablative
`matched related/unrelated allotransplant for myelodysplasia.
`
`Exh. 1039, Page 4 of 31
`
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 5
`
`Journal Publications:
`
`Laínez JM, Orcun S, Pekny JF, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ, Blau GE.
`Comparison of an assumption‐free Bayesian approach with Optimal Sampling Schedule to a
`maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing.
`Pharmacotherapy 2014;34:330‐5.
`
`Blau GE, Orcun S, Laínez JM, Reklaitis GV, Suvannasankha A, Fausel C, Anaissie EJ.
`Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin
`in a proof of principles study. Pharmacotherapy. 2013 Jul;33(7):727‐35.
`
`Kiel PJ, Fausel CA, Jones KL. Testicular germ‐cell tumors: A history of “If you don’t cure the first
`time, try, try again”. J Hematol Oncol Pharm 2012;2:85‐102.
`
`Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double‐blind,
`placebo‐controlled, Phase III crossover study evaluating the oral neurokinin‐1 antagonist
`aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients
`with germ cell tumors undergoing 5 day cisplatin‐based chemotherapy regimen: A Hoosier
`Oncology Group study. J Clin Oncol 2012;32:3998‐4003.
`
`Ormerod A, Fausel CA, Abonour R, Kiel PJ. Observations of secondary malignancies in patients
`with multiple myeloma. Clin Lymphoma Myeloma Leuk 2012;12:113‐7.
`
`Rosenbeck LL, Kiel, PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwarz J
`Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS.
`Prophylaxis with sirolimus and tacrolimus antithymocyte globulin reduces the risk of acute
`graft‐versus‐host disease without an overall survival benefit following allogeneic stem cell
`transplantation. Biol Blood Marrow Transplant 2011;17:916‐22.
`
`Greisl NJ, Fausel CA. The Evolution of Tyrosine Kinase Inhibitor Therapy: Improving Outcomes
`in Patients with Newly Diagnosed Chronic Myelogenous Leukemia. J Hematol Oncol Pharm
`2011; 1(4) 25‐32.
`
`Fausel CA. Iron chelation therapy in myelodysplastic syndrome. Am J Health Syst Pharm. 2010
`Apr;67(7 Suppl 2):S10‐4.
`
`
`Exh. 1039, Page 5 of 31
`
`
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 6
`
`Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute
`JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe
`LD. Long‐term disease‐free survival after nonmyeloablative cyclophosphamide/fludarabine
`conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
`Bone Marrow Transplant. 2010;45:1300‐8.
`
`Fausel CA. Pharmacology of anticancer agents in the elderly: the pharmacist's perspective.
`Oncology 2009;88:90.
`
`Fausel C. Targeted chronic myeloid leukemia therapy: Seeking a cure. American Journal of Health‐
`System Pharmacy. 2007;64(24 Suppl 15):S9‐15.
`
`Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Journal of Managed Care
`Pharmacy. 2007;13(8 Suppl A):8‐12.
`
`Cochran BG, Sowinski K, Fausel, C, Overholser B. Physical compatibility and chemical stability of
`mycophenolate mofetil during simulated Y‐site administration with commonly co‐administered
`drugs. Am J Health‐Systems Pharm. 2007;64(13):1410‐4.
`
`Suvannasankha A. Fausel C. Juliar BE. Yiannoutsos CT. Fisher WB. Ansari RH. Wood LL. Smith GG.
`Cripe LD. Abonour R. Final report of toxicity and efficacy of a phase II study of oral
`cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple
`myeloma: A Hoosier Oncology Group Trial, HEM01‐21. Oncologist. 2007;12(1):99‐106.
`
`Fausel CA. Novel treatment strategies for chronic myeloid leukemia. Am J Health‐Syst Pharm. 2006;
`63(Suppl 8):S15‐20.
`
`Nelson RP Jr. Cornetta K. Ward KE. Ramanuja S. Fausel C. Cripe LD. Desensitization to imatinib in
`patients with leukemia. Annals of Allergy, Asthma, & Immunology. 97(2):216‐22, 2006 Aug.
`
`Motl SE, Fausel, CA. Recurring Chemotherapy‐Associated Alopecia Areata: Case Report and
`Literature Review. Pharmacotherapy 2003;23:104‐8.
`
`Briceland LL, Lesar TS, Fausel, CA, Stein DS. Antimicrobial prescribing errors averted by pharmacists:
`Why do errors occur? J Infectious Dis Pharmacother 1999;3:1‐18.
`
`Goldman M, Chaudhary UB, Greist A, Fausel CA. Central Nervous System Infections with
`Stomatococcus mucilanginosus in Immunocompromised Hosts. Clin Infect Dis. 1998; 27: 1241‐6.
`
`Exh. 1039, Page 6 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 7
`
`McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CFM. Thrombotic thrombocytopenic
`purpura and simvastatin. The Lancet 1998; 352:1284‐5.
`
`Fausel CA, Newton DW, Driscoll DF, and Allen LV. Calcium Phosphate Supersaturation in Parenteral
`Nutrient Fluids. International Journal of Pharmaceutical Compounding. 1997; 1: 54‐59.
`
`Book Chapters:
`
`Kiel PJ., Fausel CA. Chronic Leukemias. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey
`LM eds. Pharmacotherapy: A Pathophysiologic Approach. 10th edition. New York: McGraw Hill
`Medical. 2016; In press.
`
`Fausel CA, Kiel PJ. Chronic Leukemias. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey
`LM eds. Pharmacotherapy: A Pathophysiologic Approach. 9th edition. New York: McGraw Hill
`Medical. 2014; p2277.
`
`Fausel CA, Kiel PJ. Chronic Leukemias. In: DiPiro JT, Talbot RL, Yee GC, Matzke GR, Wells BG, Posey
`LM eds. Pharmacotherapy: A Pathophysiologic Approach. 8th edition. New York: McGraw Hill
`Medical. 2011;p.2401.
`
`Fausel CA, Kiel PJ. Malignant Lymphomas. In: Chisholm‐Burns MA, Wells BG, Schwinghammer TL,
`Wells BG, Malone PM, Kolesar JM, DiPiro JT eds. Pharmacotherapy Principals and Practice. 2nd
`edition. New York McGraw Hill Medical. 2010; p.1551.
`
`Fausel CA. Neutropenia and agranulocytosis. In: Tisdale JE, Miller DA, eds. Drug‐Induced Diseases:
`Prevention, Detection and Management. Bethesda, MD: ASHP Press. 2010; p.962.
`
`Fife BL, Fausel CA. Hematopoietic dyscrasias and stem cell/bone marrow transplantation. In:
`Holland JC, Breitbart WS, Jacobsen PB, Lederberg MS, Loscalzo MJ, McCorkle R. Psycho‐Oncology.
`2nd edition. New York: Oxford University Press. 2010: p.191.
`
` Myelodysplastic Syndromes and Chronic Myeloid Leukemia.
`Fausel CA, Frame DA.
`Pharmacotherapy Self‐Assessment Program VI, Oncology Book 10. American College of Clinical
`Pharmacy. 2009.
`
`Medina PJ, Fausel CA. Cancer treatment and chemotherapy. In: DiPiro JT, Talbot RL, Yee GC,
`Matzke GR, Wells BG, Posey LM eds. Pharmacotherapy: A Pathophysiologic Approach. 7th edition.
`New York: McGraw Hill Medical. 2008; p.2085.
`
`
`
`Exh. 1039, Page 7 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 8
`
`Fausel CA. Malignant Lymphomas. In: Chisholm‐Burns MA, Wells BG, Schwinghammer TL, Malone
`PM, Kolesar JM, Rotschafer JC, DiPiro JT eds. Pharmacotherapy Principals and Practice. New York
`McGraw Hill Medical. 2007; p.1371.
`
`Curry EA, Fausel CA. Pharmacology of opioids and other analgesics. In: Fisch MJ, Burton AW eds.
`Cancer Pain Management. New York: McGraw Hill Medical. 2007; p. 23.
`
`Fausel CA. Neutropenia. In: Tisdale JE, Miller DA, eds. Drug‐Induced Diseases: Prevention, Detection
`and Management. Bethesda, MD: ASHP Press. 2005; Chapter 46.
`
`Fausel CA, Murry DJ. Hematologic Malignancies. Pharmacotherapy Self‐Assessment Program III.
`American College of Clinical Pharmacy. 2000.
`
`Content Expert Reviewer. Bone Marrow Transplantation. Pharmacotherapy Self Assessment
`Program III. American College of Clinical Pharmacy. 1999.
`
`Professional Lectures:
`
`Harvey RD, Fausel, CA. Renal function and myeloma therapeutics. Medscape CME‐certified
`Webinar. November 2015.
`
`Fausel CA. Optimizing the treatment of elderly patients with myeloma. 9th Annual Northeastern
`Regional Hematology Oncology Pharmacists Symposium. Boston, Massachusetts. October 2015.
`
`Fausel CA. Current practice guidelines review: Analyzing the latest advancements for the treatment
`of chronic myeloid leukemia. Post‐graduate Institute for Medicine CME national webinar. October
`2015.
`
`Fausel CA. Improving the quality and continuity of Multiple Myeloma care: A focus on therapeutic
`advances and treatment assessments. A Practical Guide for Pharmacists. Pharmacy Learning
`Network Continuing Pharmacy Education Meetings. Washington DC. October 2015.
`
`Fausel CA. Improving the quality and continuity of Multiple Myeloma care: A focus on therapeutic
`advances and treatment assessments. A Practical Guide for Pharmacists. Pharmacy Learning
`Network Continuing Pharmacy Education Meetings. Los Angeles, California. September 2015.
`
`Harvey RD, Fausel, CA. Understanding Multiple Myeloma, It’s treatment and new discoveries: Part
`II. American Society of Health‐Systems Pharmacy CE National Webcast. August 2015.
`
`Exh. 1039, Page 8 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 9
`
`Fausel CA, Harvey RD. Understanding Multiple Myeloma, It’s treatment and new discoveries: Part I.
`American Society of Health‐Systems Pharmacy CE National Webcast. August 2015.
`
`Fausel CA. Novel therapeutic options for Non‐Hodgkin Lymphoma. Oncology Pharmacy Education
`Network (OPEN) provided by the Association of Community Cancer Centers. New Brunswick, New
`Jersey. May 2015.
`
`Fausel CA. Novel therapeutic options for Non‐Hodgkin Lymphoma. Oncology Pharmacy Education
`Network (OPEN) provided by the Association of Community Cancer Centers. Charlotte, North
`Carolina. July 2015.
`
`Fausel CA. Novel therapeutic options for non‐Hodgkin Lymphoma. Oncology Pharmacy Education
`Network (OPEN) provided by the Association of Community Cancer Centers. Fort Lauderdale,
`Florida. June 2015.
`
`Fausel CA. Improving the quality and continuity of Multiple Myeloma care: A focus on therapeutic
`advances and treatment assessments. A Practical Guide for Pharmacists. Pharmacy Learning
`Network Continuing Pharmacy Education Meetings. Orlando, Florida. May 2015.
`
`Fausel CA. Novel therapeutic options for Non‐Hodgkin Lymphoma. Oncology Pharmacy Education
`Network (OPEN) provided by the Association of Community Cancer Centers. New Brunswick, New
`Jersey. May 2015.
`
`Fausel CA. Oncology Practice Administration. ASHP/ACCP Board Certification Oncology Pharmacist
`review course. Dallas, Texas. May 2015.
`
`Fausel CA, Whited L. Pharmacy Perspectives in Multiple Myeloma: Tailoring therapy in complex
`situations. Medscape CME‐certified National Webcast. January 2015.
`
`Fausel CA. Oral Chemotherapy. Grand Rounds. Indiana University Simon Cancer Center.
`Indianapolis, Indiana. October 2014.
`
`Fausel CA. Expanding options for treatment in Non‐Hodgkin Lymphoma: Progress across multiple
`histopathologic subtypes. 8th Annual Northeastern Regional Hematology Oncology Pharmacists
`Symposium. Boston, Massachusetts. October 2014.
`
`Fausel CA. Multiple Myeloma: Current and future directions. Indiana University School of Medicine
`Miles for Myeloma Survivorship Dinner. Indianapolis, Indiana. October 2014.
`
`Exh. 1039, Page 9 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 10
`
`Fausel CA, Harvey RD. Improving Outcomes in Chronic Myeloid Leukemia: A 2014 Update for
`Managed Care Professionals. National Continuing Pharmacy Education Webcast. June 2014.
`
`Fausel CA. Oncology Practice Administration. ASHP/ACCP Board Certification Oncology Pharmacist
`review course. Washington DC. May 2014.
`
`Fausel CA. Improving Outcomes and Quality of Life for Patients with Multiple Myeloma: A Practical
`Guide for Pharmacists. Pharmacy Learning Network Continuing Pharmacy Education Meetings.
`April 2014, Philadelphia PA. Raleigh North Carolina. May 2014.
`
`Fausel CA. Multiple Myeloma: Current approaches to managing relapsed and refractory disease.
`Virginia Society of Health‐System Pharmacists Spring Meeting. Richmond, Virginia. April 2014.
`
`Fausel CA, Harvey RD. New and Emerging Approaches in Relapsed or Refractory Myeloma – The
`Pharmacist’s Perspective. Medscape CME national webcast. December 2013.
`
`Improving Medical Management of Multiple Myeloma: Evidence‐Based Guidance on Therapy
`Selection and Treatment of Side Effects. Pharmacy Learning Network Continuing Pharmacy
`Education Meeting. Washington DC. November 2013.
`
`Multiple Myeloma Treatment Strategies to Meet the Challenges of New and Refractory Disease.
`North Carolina Academy of Pharmacists Annual Convention. Oklahoma Society of Health‐System
`Pharmacists Fall Meeting. Tulsa, Oklahoma. October 2013.
`
`Multiple Myeloma Treatment Strategies to Meet the Challenges of New and Refractory Disease.
`North Carolina Academy of Pharmacists Annual Convention. Raleigh, North Carolina. October
`2013.
`
`Multiple Myeloma Treatment Strategies to Meet the Challenges of New and Refractory Disease.
`Kentucky Society of Health‐System Pharmacists Fall Meeting. French Lick, Indiana. October 2013.
`
`Improving Medical Management of Multiple Myeloma: Evidence‐Based Guidance on Therapy
`Selection and Treatment of Side Effects. Pharmacy Learning Network Continuing Pharmacy
`Education Meeting. San Mateo, California. September 2013.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. July 2013.
`
`Targeted therapy: A hem/onc fellow’s toolbox. Hematology/oncology fellows conference. Indiana
`University School of Medicine. Indianapolis, Indiana. July 2013.
`
`Exh. 1039, Page 10 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 11
`
`Managing Risks in Patients with Hematologic Malignancies: What Pharmacists Need to Know.
`University of Tennessee College of Pharmacy Continuing Education/Advanced Studies in Medicine
`Continuing Pharmacy Education national webcast. June 2013.
`
`Chronic Leukemias and the Lymphomas. ASHP/ACCP Board Certification Oncology Pharmacist
`review course. Chicago, Illinois. May 2013.
`
`Improving Medical Management of Multiple Myeloma: Evidence‐Based Guidance on Therapy
`Selection and Treatment of Side Effects. Pharmacy Learning Network Continuing Pharmacy
`Education Meeting. Chicago, Illinois. April 2013.
`
`Improving Medical Management of Multiple Myeloma: Evidence‐Based Guidance on Therapy
`Selection and Treatment of Side Effects. Pharmacy Learning Network Continuing Pharmacy
`Education Meeting. Orlando, Florida. March 2013.
`
`Dosing and drug administration in multiple myeloma: Optimizing treatments for individual patients.
`Medscape CME national webcast. October 2012.
`
`Multiple myeloma treatment and supportive care: discerning the role of available and
`investigational therapies. Pharmacy Learning Network Continuing Pharmacy Education program.
`Los Angeles, CA. September 2012.
`
`Multiple myeloma treatment and supportive care: discerning the role of available and
`investigational therapies. Pharmacy Learning Network ACPE program. Washington DC. August
`2012.
`
`Targeted therapy: A hem/onc fellow’s toolbox. Hematology/oncology fellows conference. Indiana
`University School of Medicine. Indianapolis, Indiana. July 2012.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. July 2012.
`
`The chemotherapy talk. Hematology/oncology fellows conference. Indiana University School of
`Medicine. Indianapolis, Indiana. July 2012.
`
`Oncology symposium: Adherence with oral therapy in chronic myeloid leukemia. Monongahela
`Valley Hospital, Carroll, Pennsylvania. May 2012.
`
`ASHP/ACCP Board Certification Oncology Pharmacist review course. Topics presented:
`CML/CLL/MDS, lymphomas/multiple myeloma. Denver, CO. May 2012.
`
`Exh. 1039, Page 11 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 12
`
`Multiple myeloma treatment and supportive care: discerning the role of available and
`investigational therapies. Pharmacy Learning Network ACPE program. Chicago, IL. May 2012.
`
`Multiple myeloma treatment and supportive care: discerning the role of available and
`investigational therapies. Pharmacy Learning Network ACPE program. Philadelphia, PA. March
`2012.
`
`Tyrosine kinase inhibitors in hematology: focus on the Philadelphia chromosome. Hematology
`Oncology Pharmacists Association Annual Conference. Orlando, FL. March 2012.
`
`The Future of Cancer Care: Lessons learned in Chronic Myeloid Leukemia. Institute for Medical
`Education and Research CME Program. Chicago, IL. February 2012.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Washington DC. September 2011
`
`Targeted therapy: A hem/onc fellow’s toolbox. Hematology/oncology fellows conference. Indiana
`University School of Medicine. Indianapolis, Indiana. August 2011.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. July 2011.
`
`The chemotherapy talk. Hematology/oncology fellows conference. Indiana University School of
`Medicine. Indianapolis, Indiana. July 2011.
`
`Chronic myeloid leukemia: A model for modern oncology drug development. Indiana University
`Health Continuing Education Symposium. Indianapolis, IN. June 2011.
`
`Catching up to metastatic melanoma: The Emerging Role of Targeted and Immunotherapies.
`Pharmacy Learning Network ACPE program. Newark, New Jersey. May 2011.
`
`ASHP/ACCP Board Certification Oncology Pharmacist review course. Topics presented:
`CML/CLL/MDS, lymphomas/multiple myeloma. San Antonio, TX. April 2011.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Philadelphia, Pennsylvania. November 2010
`
`Chronic myeloid leukemia: Considerations for selection and managing therapy. Virginia Society of
`Health Systems Pharmacists. Norfolk, Virginia. October 2010.
`
`
`Exh. 1039, Page 12 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 13
`
`Chronic myeloid leukemia: Considerations for selection and managing therapy. Connecticut Society
`of Health‐System Pharmacists. Westbrook, CT. October 2010.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Washington DC. September 2010
`
`Targeted therapy: A hem/onc fellow’s toolbox. Hematology/oncology fellows conference. Indiana
`University School of Medicine. Indianapolis, Indiana. September 2010.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. July 2010.
`
`The chemotherapy talk. Hematology/oncology fellows conference. Indiana University School of
`Medicine. Indianapolis, Indiana. July 2010.
`
`ASHP/ACCP Board Certification Oncology Pharmacist review course. Topics presented:
`CML/CLL/MDS, lymphomas/multiple myeloma. San Diego, CA. May 2010.
`
`Chronic myeloid leukemia: Considerations for selection and managing therapy. ASHP Advantage
`ACPE webinar. Indianapolis, Indiana. May 2010.
`
`Chronic myeloid leukemia: Considerations for selection and managing therapy. ASHP Advantage
`ACPE webinar. Indianapolis, Indiana. April 2010.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Uniondale, New York. May 2010.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Dallas, Texas. May 2010.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Los Angeles, California. March 2010.
`
`Current and emerging multiple myeloma management considerations. Pharmacy Learning
`Network ACPE program. Orlando, Florida. March 2010.
`
`Survivorship lecture. Support for people with oral and head and neck cancer chapter meeting.
`Indianapolis, Indiana. December 2009.
`
`
`
`Exh. 1039, Page 13 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 14
`
`Survivorship lecture. Leukemia and lymphoma chapter meeting. Indianapolis, Indiana. November
`2009.
`
`Patient Considerations concerning side effects of newer treatments multiple myeloma treatments.
` Miles for Myeloma survivorship dinner. Indiana University Simon Cancer Center, Indianapolis,
`Indiana. October 2009.
`
`Survivorship lecture. Support for people with oral and head and neck cancer chapter meeting.
`Indianapolis, Indiana. October 2009.
`
`Pharmacotherapeutic approaches to the management of multiple myeloma. Pharmacy Learning
`Network ACPE program. Tampa, Florida. November 2009.
`
`Chemotherapy toxicity cases vignettes. Fellows conference, Division of Hematology/Oncology,
`Indiana University School of Medicine. Indianapolis, Indiana. October 2009.
`
`Targeted therapy: A hem/onc fellow’s toolbox. Hematology/oncology fellows conference. Indiana
`University School of Medicine. Indianapolis, Indiana. October 2009.
`
`Pharmacotherapeutic approaches to the management of multiple myeloma. Pharmacy Learning
`Network ACPE program. Chicago, Illinois. September 2009.
`
`An update in ITP. Hematology Oncology Pharmacists Association Georgia chapter meeting.
`Atlanta, Georgia. August 2009.
`
`Relevant interactions with antineoplastic drugs. Oncology Nursing Society, Central Indiana chapter
`meeting. Indianapolis, Indiana. August 2009.
`
`An update in ITP. Oncology Nursing Society South Carolina chapter meeting. Charleston, South
`Carolina. July 2009.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. July/August 2009.
`
`An overview of neutropenic fever. Hematology/oncology fellows conference. Indiana University
`School of Medicine. Indianapolis, Indiana. July 2009.
`
`The chemotherapy talk. Hematology/oncology fellows conference. Indiana University School of
`Medicine. Indianapolis, Indiana. July 2009.
`
`
`Exh. 1039, Page 14 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 15
`
`Iron Chelation Therapy in MDS. Hematology Oncology Pharmacists Association meeting, Miami,
`Florida. June 2009.
`
`ASHP/ACCP Board Certification Oncology Pharmacist review course. Topics presented:
`CML/CLL/MDS, lymphomas/multiple myeloma, and sarcomas. Baltimore, Maryland. April 2009.
`
`Question and answer session with the pharmacist. Camp Bluebird Cancer Survivors Camp,
`Mooresville, Indiana. April 2009.
`
`Chemotherapy‐induced pulmonary toxicity. Fellows conference, Division of Pulmonary Medicine,
`Indiana University School of Medicine. Indianapolis, Indiana. March 2009
`
`Chemotherapy‐induced nausea and vomiting case vignettes. Fellows conference, Division of
`Hematology/Oncology, Indiana University School of Medicine. Indianapolis, Indiana. January 2009.
`
`CML Update 2008: BCOP review lecture. American Society of Health‐Systems Pharmacy midyear
`meeting, Louisville, Kentucky. December 2008.
`
`Chemotherapy hypersensitivity reactions. Fellows conference, Division of Hematology/Oncology,
`Indiana University School of Medicine. Indianapolis, Indiana. October 2008.
`
`CML Update 2008: BCOP review lecture. American College of Clinical Pharmacy annual meeting,
`Louisville, KY. June 2008.
`
`Cancer Pain Management. Fellows conference, Division of Hematology/Oncology, Indiana
`University School of Medicine. Indianapolis, Indiana. August 2008.
`
`ASCO Review: Hematologic malignancies and patient care. Central Indiana Oncology Nursing
`Society Annual Meeting. Indianapolis, Indiana. August 2008.
`
`An overview of neutropenic fever. Hematology/oncology fellows conference. Indiana University
`School of Medicine. Indianapolis, Indiana. July 2008.
`
`Clinical trials of antifungal agents in cancer patients. Hematology/oncology fellows conference.
`Indiana University School of Medicine. Indianapolis, Indiana. June 2008.
`
`ASCO review: Hematologic malignancies and patient care. Hematology Oncology Pharmacists
`Association meeting, Anaheim, California. June 2008.
`
`
`
`Exh. 1039, Page 15 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page 16
`
`CML Update 2008: BCOP review lecture. Hematology Oncology Pharmacists Association meeting,
`Anaheim, California. June 2008.
`
`Institutional Pharmacy Practice Research. Hematology Oncology Pharmacists Association meeting,
`Anaheim, California. June 2008.
`
`ASHP/ACCP Board Certification Oncology Pharmacist review course. Topics presented:
`CML/CLL/MDS, lymphomas/multiple myeloma, and sarcomas. Scottsdale, Arizona. May 2008.
`
`An introduction to pharmacogenomics. National Association of Clinical Nurse Specialists, Indiana
`Chapter. Indianapolis, Indiana. November 2007.
`
`Oral chemotherapy agents. CRA/Nurse/Pharmacist Educational forum. Eastern Cooperative
`Oncology Group Fall Meeting. Fort Lauderdale, Florida. November 2007.
`
`Handling investigational drugs. Clinical Research Office, Indiana University School of Medicine.
`Indianapolis, Indiana. October 2007.
`
`Pharmacology and toxicity of antineoplastics agents I and II. Hematology/oncology fellows
`conference. Indiana University School of Medicine. Indianapolis, Indiana. August 2007.
`
`Updated ASCO guidelines for chemotherapy‐induced nausea and vomiting. Hematology/oncology
`fellows conference. Indiana University School of Medicine. Indianapolis, Indiana. August 2007.
`
`An introduction to pharmacogenomics. Indiana University School of Nursing/Clarian Health
`Nursing Continuing Education Symposium. Indianapolis, Indiana. August 2007.
`
`The chemotherapy talk. Hematology/oncology fellows conference. Indiana University School of
`Medicine. Indianapolis, Indiana. July 2007.
`
`An overview of neutropenic fever. Hematology/oncology fellows conference. Indiana University
`School of Medicine. Indianapolis, Indiana. July 2007.
`
`Statistics in cancer clinical trials. Abraxis Oncology Training Seminar. Bridgewater, New Jersey. July
`2007.
`
`Targeted chronic myeloid leukemia therapy: seeking cure. American Society of Heath‐Systems
`Pharmacists Annual Meeting. San Francisco, California. June 2007.
`
`
`
`Exh. 1039, Page 16 of 31
`
`
`
`Christopher A. Fausel, Pharm.D. MHA BCOP
`Curriculum Vitae
`Page